Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other financing activities (2016 - 2025)

Historic Other financing activities for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Q3 2025 value amounting to $1000.0.

  • Ironwood Pharmaceuticals' Other financing activities rose 10001.16% to $1000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 13155.72%. This contributed to the annual value of $11.0 million for FY2024, which is 17498.13% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Other financing activities stood at $1000.0, which was up 10001.16% from $88000.0 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Other financing activities high stood at $17.5 million for Q4 2021, and its period low was -$8.7 million during Q3 2024.
  • Moreover, its 5-year median value for Other financing activities was $1.6 million (2023), whereas its average is $3.1 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Other financing activities soared by 88776.17% in 2021, and later crashed by 6667692.31% in 2024.
  • Ironwood Pharmaceuticals' Other financing activities (Quarter) stood at $17.5 million in 2021, then crashed by 70.44% to $5.2 million in 2022, then plummeted by 66.85% to $1.7 million in 2023, then soared by 417.95% to $8.9 million in 2024, then plummeted by 99.99% to $1000.0 in 2025.
  • Its Other financing activities stands at $1000.0 for Q3 2025, versus $88000.0 for Q2 2025 and $6000.0 for Q1 2025.